# Ryan J. Sullivan

Source: https://onco.cc/people/ryan-sullivan/  
OnCo record `ryan-sullivan` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Ryan Sullivan is a melanoma trialist and a leading voice on managing immunotherapy side effects.

## Summary

Ryan J. Sullivan is Associate Director of the Melanoma Program at Massachusetts General Hospital Cancer Center. He is a melanoma trialist and a leading voice on managing the side effects of immunotherapy, having co-authored society guidelines on immune-related adverse events. His selected paper is the ASCO guideline update on managing immune-related adverse events in patients treated with immune checkpoint inhibitors. He leads melanoma clinical trials at MGH and studies how to sequence targeted and immune therapy, including DREAMseq-style questions.

## Fields

- Kind: Person
- Last checked: 2026-09-08
- Role: Associate Director, Melanoma Program
- Specialisms: Melanoma; Immune-related adverse events; Targeted and immune therapy sequencing

## Sources

- MGH profile: https://www.massgeneral.org/doctors/19412/ryan-sullivan
- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Sullivan%20RJ%5BAuthor%5D

## Connected records

- cancers: [Melanoma](https://onco.cc/cancers/melanoma/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- institutions: [Massachusetts General Hospital Cancer Center](https://onco.cc/institutions/mgh/)
- key papers: [KEYNOTE-942: a personalised mRNA cancer vaccine plus pembrolizumab after melanoma surgery](https://onco.cc/key-papers/paper-keynote-942-lancet-2024/)

---
JSON: https://onco.cc/api/v1/entities/ryan-sullivan.json